tbuckley/cabot-search huggingface dataset:
A PREVIOUS HAMSTRING INJURY AFFECTS THE KICKING TECHNIQUE AND THIS IS INFLUENCED BY GENDER AND LIMB DOMINANCE
Authors: Archit Navandar, Santiago Veiga, Carlos García, Gonzalo Torres Marquéz, David Chorro, Enrique Navarro
Journal: British Journal of Sports Medicine (2017)

Background Although the hamstring muscle group gets loaded during the kicking motion, the effect of a previous hamstring injury on the kicking skill has not been studied in detail. Objective To the study the effect of a previous hamstring injury on the kicking technique, and how gender and limb dominance influences the same. Design Observational study. Participants were required to kick the ball into a target 7 m away using a four step run-up. Five valid kicks were taken from the dominant and non-dominant limb each. Setting Laboratory conditions on FIFA approved artificial turf, with a three-dimensional Vicon motion capture system at 200Hz and a Kistler force platform at 1000Hz. with participants belonging to Spanish First (women) and Second (men) Division teams. Participants 45 professional soccer players (females=26, males=19) who belonged to clubs that had the same number of training sessions and matches per week. Main Outcome Measurements Ball velocities, kinematic and kinetic data for the hip and knee of the kicking leg in the sagittal plane, and the reaction forces for the ground and the support leg. 3-way ANOVA was used to compare the data. Results Previously injured female athletes had a lower peak hip velocity in the dominant limb kicks; and a smaller knee flexion angle, and a lower hip flexion velocity in the non-dominant limb kicks. Conclusions Kicking technique is affected by a previous hamstring injury in females especially in phases where the hamstring muscles are the most active. Differences in male soccer players were not seen. Thus these injuries must be treated differently in male and female soccer players, and whether the injury occurred in the dominant or non-dominant limb. An additional study with a greater number of previously injured athletes would be necessary to provide conclusive results.
Response of Strain A Female Mice to Small Amounts of &lt;italic&gt;0&lt;/italic&gt;-Aminoazotoluene
Authors: Howard B. Andervont, Jesse E. Edwards
Journal: JNCI Journal of the National Cancer Institute (1943)

Response of Strain A Female Mice to Small Amounts of 0-Aminoazotoluene Get access Howard B. Andervont, Howard B. Andervont principal biologist Search for other works by this author on: Oxford Academic PubMed Google Scholar Jesse E. Edwards Jesse E. Edwards research fellow National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 3, Issue 4, February 1943, Pages 355–358, https://doi.org/10.1093/jnci/3.4.355 Published: 01 February 1943
The Statistical Significance of the Efficacy Results in a Randomized Clinical Trial
Authors: Zheng Su
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen
Authors: B.J. Werth, R. Jain, A. Hahn, L. Cummings, T. Weaver, A. Waalkes, D. Sengupta, S.J. Salipante, R.M. Rakita, S.M. Butler-Wu
Journal: Clinical Microbiology and Infection (2017)
The REL-Protocol PhilosoPhi34 - an Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia (CML) Patients - Confirms Early Clearance of Bone Marrow CD34+/Lin-Ph+ Cells
Authors: Ester Pungolino, Gabriella De Canal, Mariella D'adda, Alessandra Perego, Mauro Turrini, Ester Maria Orlandi, Alessandra Trojani, Lorenza Borin, Alessandra Iurlo, Maria Luisa Latargia, Simona Malato, Maria Cristina Carraro, Stefania Brusorio, Chiara Elena, Francesco Spina, Milena Lodola, Salvatore Artale, Michela Anghilieri, Cristina Bucelli, Maria Luisa Pioltelli, Silvia Cantoni, Giuseppe Rossi, Enrica Morra, Roberto Cairoli
Journal: Blood (2016)
Brain–Heart Interaction
Authors: Zhili Chen, Poornima Venkat, Don Seyfried, Michael Chopp, Tao Yan, Jieli Chen
Journal: Circulation Research (2017)

Neurocardiology is an emerging specialty that addresses the interaction between the brain and the heart, that is, the effects of cardiac injury on the brain and the effects of brain injury on the heart. This review article focuses on cardiac dysfunction in the setting of stroke such as ischemic stroke, brain hemorrhage, and subarachnoid hemorrhage. The majority of post-stroke deaths are attributed to neurological damage, and cardiovascular complications are the second leading cause of post-stroke mortality. Accumulating clinical and experimental evidence suggests a causal relationship between brain damage and heart dysfunction. Thus, it is important to determine whether cardiac dysfunction is triggered by stroke, is an unrelated complication, or is the underlying cause of stroke. Stroke-induced cardiac damage may lead to fatality or potentially lifelong cardiac problems (such as heart failure), or to mild and recoverable damage such as neurogenic stress cardiomyopathy and Takotsubo cardiomyopathy. The role of location and lateralization of brain lesions after stroke in brain-heart interaction; clinical biomarkers and manifestations of cardiac complications; and underlying mechanisms of brain-heart interaction after stroke, such as the hypothalamic-pituitary-adrenal axis; catecholamine surge; sympathetic and parasympathetic regulation; microvesicles; microRNAs; gut microbiome, immunoresponse, and systemic inflammation, are discussed.
T Cell Zone Resident Macrophages Silently Dispose of Apoptotic Cells in the Lymph Node
Authors: Myriam Baratin, Léa Simon, Audrey Jorquera, Clément Ghigo, Doulaye Dembele, Jonathan Nowak, Rebecca Gentek, Stephan Wienert, Frederick Klauschen, Bernard Malissen, Marc Dalod, Marc Bajénoff
Journal: Immunity (2017)
Psychoanalysis and Culture
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Activated platelets canLiblilla be imaged by activation-specific glycoprotein IIb/IIIa antibodies conjugated to iron oxide microparticles in an ex vivo magnetic resonance imaging mouse model
Authors: C von zur Muehlen, Z Ali, J Schneider, M McAteer, K Channon, C Bode, K Peter, R Choudhury
Journal: Journal of the American College of Cardiology (2007)
炎症性腸疾患:オンコスタチンMは腸の炎症を引き起こし,炎症性腸疾患の患者での腫瘍壊死因子中和療法への応答性を予測する
Authors: West Nathaniel R, Hegazy Ahmed N, Bullers Samuel J, Stockenhuber Krista, Friedrich Matthias, Ryzhakov Grigory, Powrie Fiona, This Sebastien, Arancibia Carolina, Bailey Adam, Barnes Ellie, Bird‐Lieberman Beth, Brain Oliver, Braden Barbara, East James, Keshav Satish, Klenerman Paul, Leedham Simon, Simmons Alison, Travis Simon P L, Uhlig Holm, Owens Benjamin M J, Linggi Bryan, Baribaud Frederic, Brodmerkel Carrie, Plevy Scott E, Buonocore Sofia, Coccia Margherita, Pott Johanna, Maloy Kevin J, Goertz Dieter, Mueller‐Newen Gerhard, Cieluch Constanze, Kuehl Anja A, Rahman Nahid, Owens Raymond J, Collier Jane, Howarth Lucy, Palmer Rebecca, Rodrigues Astor, Sullivan Peter
Journal: Nature Medicine (2017)
NECK FUNCTION IN ELITE MALE RUGBY UNION PLAYERS: RESULTS FROM A PILOT FOR AN INTERVENTION STUDY
Authors: Bianca Zietsman, Espen Aag Holth, Peter McCarthy
Journal: British Journal of Sports Medicine (2017)

Background Elite male rugby union players have a decreased active cervical spine rage of motion (ACROM), the severity correlates to both number of years playing and position (Lark &amp; McCarthy 2007, Scher 1990), but a measurable decrease occurs over a season (Lark &amp; McCarthy 2010). Objective The aim was to ascertain whether a neck prehabiliation protocol, using body weighted suspension bands (FKPro) , could affect the expected attrition in cervical spine function. Design ACROM of all participants was measured with a CROM device (Capuano-Pucci et al 1991), using a Latin square randomisation to eliminate order effects. Likert scale questionnaires were also provided to all participants (pain and associated symptomatology). Setting A clinical setting within semi professional Welsh Rugby Union Club. Participants 19 participants were recruited from Beddau RFC first XV. All players were included in the study, unless the player was ruled out from training or playing for clinical reasons. Height 181.5 (±5.9) cm, weight 98.7 (±17.2 kg, age 23.9 (±4.2) yrs. Interventions (or Assessment of Risk Factors) Participants underwent a progressive 8 week intervention, using the FKPRO with neck harness. Postural and isometric holds were performed of 30 seconds duration in four directions under clinical supervision twice weekly (training days). Main Outcome Measurements Change in ACROM. Results Table 1 Total flexion/ extension Total rotation Total lateral flexion PRE intervention 122.8 (±14.2) 123.0 (±19.5) 89.3 (±14.3) POST intervention 126.4 (±16.7) 128.6 (±15.4) 87.1 (±13.8) Conclusions The apparent lack of decrease in ACROM (i.e. no statistical difference) could indicate that the prehabilitation protocol helps compensate for the effects of participation in the contact sport on the cervical spine of athletes. A full study (duration of the playing season) is currently underway.
癌へのsiRNAのデリバリーに対する機能的エクソソーム類似物:in vitroとin vivoでの評価
Authors: Yang Zhaogang, Xie Jing, Zhu Jing, Kang Chen, Chiang Chiling, Wang Xinmei, Wang Xiaobing, Kuang Tairong, Chen Feng, Chen Zhou, Zhang Aili, Yu Bo, J Lee Robert, Teng Lesheng, Lee L. James
Journal: Journal of Controlled Release (2016)
Patient Care Is All About Stories
Authors: Louis R. Caplan
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
Authors: Dylan J. Martini, Aly-Khan A. Lalani, Dominick Bossé, John A. Steinharter, Lauren C. Harshman, F. Stephen Hodi, Patrick A. Ott, Toni K. Choueiri
Journal: Journal for ImmunoTherapy of Cancer (2017)

<h3>Background</h3> Monoclonal antibodies targeting the PD-1/PD-L1 axis have gained increasing attention across many solid tumors and hematologic malignancies due to their efficacy and favorable toxicity profile. With more than 1 agent now FDA-approved in a wide variety of tumor types, and with others in clinical trials, it is becoming more common that patients present to clinic for potential treatment with a second PD-1/PD-L1 inhibitor. <h3>Case presentation</h3> In this report, we present two patients with renal cell carcinoma and one with melanoma who received PD-1/PD-L1 inhibitors. Upon progression on their first-line PD-1/PD-L1 inhibitors, these patients received a different PD-1 inhibitor (nivolumab in all cases) and all had progressive disease as their best response to the subsequent PD-1 inhibitor. The reported clinical information focuses on the course of the disease and the responses to all treatment regimens. <h3>Conclusions</h3> Clinicians should refrain from using multiple PD-1/PD-L1 inhibitors sequentially outside of clinical trials until there is sufficient data to support this practice routinely. Prospective studies that allow prior treatment with PD-1/PD-L1 are needed to validate the efficacy and safety of these drugs in the second line or later setting. Furthermore, ongoing efforts that aim to identify mechanisms of resistance to immunotherapy will be informative and may ultimately assist physicians in select the optimal treatment following progression on PD-1/PD-L1 inhibitor.
Disturbances of Sugar Metabolism in Gastric Cancer
Authors: Heron O. Singher
Journal: JNCI Journal of the National Cancer Institute (1945)

Disturbances of Sugar Metabolism in Gastric Cancer Get access Heron O. Singher Heron O. Singher Memorial Hospital for the Treatment of Cancer and Allied Diseases, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 5, Issue 5, April 1945, Pages 371–373, https://doi.org/10.1093/jnci/5.5.371 Published: 01 April 1945
Cancer-associated macrophage-like cells as prognostic indicators of overall survival in a variety of solid malignancies.
Authors: Daniel Adams, Diane K Adams, Steven H. Lin, Massimo Cristofanilli, Raymond C. Bergan, Jeffrey R Marks, Stuart S Martin, Saranya Chumsri, Thai Huu Ho, Rena G. Lapidus, Susan Tsai, Cha-Mei Tang, R. Katherine Alpaugh
Journal: Journal of Clinical Oncology (2017)

11503 Background: Cancer Associated Macrophage-Like cells (CAMLs) are a recently described circulating stromal cell subtype commonly found in the peripheral blood of patients in all stages of solid malignancies and in a variety of cancer subtypes. However, while their biological association to cancer is being studied, their clinical utilization as it relates to cancer prognosis has not been evaluated. Methods: A two year prospective study was undertaken to evaluate the relationship of CAMLs and overall survival (OS) in 6 solid tumor types. The single blind multi-institutional study consisted of 269 stage I-IV patients; breast (n = 57), esophageal (n = 21), prostate (n = 43), pancreatic (n = 59), lung (n = 54), and renal cell (n = 35), in treatment (n = 134) and untreated baseline (n = 135). 7.5mL of whole blood was filtered by CellSieve microfiltration assay and CAMLs enumerated, as previously described. Patients were grouped by CAML number ( &lt; 6 or ≥6) and by size ( &lt; 49 or ≥50 µm) to evaluate hazard ratios (HR) by censored univariate &amp; multivariate analysis. Results: CAMLs were identified in 93% of samples, averaging 8.2 CAMLs/7.5mL blood sample, and found in all 6 cancers at baseline and during treatment. Average CAML number was associated with disease stage and CAML positivity was 4.4 &amp; 80% (Stage I), 4.7 &amp; 93% (Stage II), 9.3 &amp; 98% (Stage 3), 12.1 &amp; 97% (Stage IV). Univariate analysis of patients (n = 269) stratified by ≥6 CAMLs had reduced OS (HR = 1.8, 95%CI 1.1-2.9, p = 0.03). Further, CAML size also had reduced OS in patients with ≥50 µm CAMLs (HR = 2.7, 95%CI 1.8-4.0, p &lt; 0.0001). Conclusions: Our data suggests that in solid malignancies, CAML number and size appear to clinically correlate with OS in early and late stage disease. Given these results relating CAMLs with OS, further analysis is warranted to determine if CAMLs can serve as a clinically-relevant blood-based marker.
タウPET放射性トレーサとその臨床的応用の開発における進歩【Powered by NICT】
Authors: Okamura Nobuyuki, Harada Ryuichi, Furukawa Katsutoshi, Furumoto Shozo, Tago Tetsuro, Yanai Kazuhiko, Arai Hiroyuki, Kudo Yukitsuka
Journal: Ageing Research Reviews (2016)
08.25 In vitro characterisation of circulating fibrocytes from systemic sclerosis patients with diffuse disease: early results
Authors: Stefano Soldano, Renata Brizzolara, Paola Montagna, Amelia Chiara Trombetta, Barbara Ruaro, Paola Contini, Alberto Sulli, Sabrina Paolino, Carmen Pizzorni, Maurizio Cutolo
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Circulating fibrocytes seem an important source of fibroblasts/myofibroblasts in physiological and pathological tissue remodelling, such as in tissue repair and in fibrosing diseases (ie, systemic sclerosis, SSc).<sup>1–3</sup> In addition, fibrocytes seem to express class II major histocompatability complex molecules (HLA-DP, -DQ, and -DR). We aimed to isolate fibrocytes from peripheral blood mononuclear cells (PBMCs) of healthy subjects and SSc patients and to identify them using their specific markers: CD45, HLA-DR, collagen I, and the chemokine receptor CXCR4.<sup>2</sup> <h3>Materials and methods</h3> PBMCs were collected, at basal time (t0), from 5 healthy subjects (CNTs) and 9 SSc patients, affected by diffuse disease (dSSc) and with treatment limited to vasodilators (prostacyclin) and aspirin. PBMCs isolated from 7 among the SSc patients were cultured on fibronectin-coated plates. The non-adherent cells were removed and after 8 days (t8) of culture (standardised time), the adherent cells were lifted through incubation in 0.05% EDTA (ice-cold). Fibrocyte identification (at both t0, t8), was done by fluorescence-activated cell sorter analysis (FACS), using anti-CD45, anti-collagen type I, anti-CXCR4 and HLA-DR monoclonal antibodies. <h3>Results</h3> At basal time (t0), among the CD45+ cells, the percentage of fibrocytes, identified as triple positive (CD45+, coll I+, CXCR4+), resulted 0.44%±0.31% in healthy subjects (CNTs) and 2.10%±2.6% in SSc patients. In addition, the HLA-DR expression on fibrocytes in both CNTs and SSc patients showed low values (7.06%±6.1% and 24.2%±22.2%, respectively). Interestingly, after 8 days (t8) of culture, fibrocytes CD45+, coll I+, CXCR4+ from the SSc patients increased up to 45.88%±23.71%, compared to basal time (t0). In addition, at t8, fibrocytes from SSc patients strongly increased HLA-DR+ expression (88.2%±24.8%). <h3>Conclusion</h3> Fibrocytes isolated from circulating progenitor cells (CPCs) of healthy subjects and SSc patients were confirmed to express CD45, coll I and CXCR4 molecules, but in very low percentage. Already after 8 days of culture, fibrocytes (CD45+, coll I+ and CXCR4+) from SSc patients, increased up to 48% and the HLA-DR expression increased up to 64%. Additional markers for these CPCs are now under test to further characterise their phenotype(s) vs healthy controls. <h3>References</h3> 1. Chesney J, <i>et al</i>. <i>Proc Natl Acad Sci</i><b>1997</b>;94:6307–6312; 2. Herzoga EL, <i>et al</i>. <i>Experimental Haematology</i><b>2010</b>;38:548–556. 3. Brunasso A.M. <i>et al</i>. <i>F1000Research</i><b>2016</b>;5:723.
グリア芽腫治療のためのナノ粒子の特異的浸透のための相乗的なターゲッティングテネイシンCとニューロピリン‐1【Powered by NICT】
Authors: Kang Ting, Zhu Qianqian, Jiang Di, Feng Xingye, Feng Jingxian, Jiang Tianze, Yao Jianhui, Jing Yixian, Song Qingxiang, Jiang Xinguo, Gao Xiaoling, Chen Jun
Journal: Biomaterials (2016)
B Cells of the Proliferative Fraction of CLL Clones Exhibit Activated B-Cell and Myeloid-Cell Signatures Suggesting Enhanced Antigen-Presentation, Integrin Responsiveness, and IL-4 Receptiveness: Additional Targets for CLL Therapy
Authors: Xiao-Jie Yan, Florencia Palacios, Wentian Li, Sophia Yancopoulos, Carlo Calissano, Jacqueline C. Barrientos, Steven L. Allen, Jonathan E. Kolitz, Kanti Rai, Nicholas Chiorazzi
Journal: Blood (2016)